Global OTC Drugs Market Outlook, 2031

The global over-the-counter drugs industry covers medicines that consumers can buy without a prescription, including pain relievers, cough, cold and flu remedies, allergy medicines, digestive health products, skin treatments, smoking cessation aids, sleep aids, eye and ear care, oral care medicines, vitamins, minerals and supplements sold in some markets under medicine rules, and newer categories such as emergency contraception, daily oral contraception and naloxone. OTC medicines treat minor and self-limiting conditions and are an important part of self-care, reducing pressure on doctors and health systems. The market is led by consumer health companies, including Haleon, formed from GSK's consumer business with brands such as Advil, Panadol, Sensodyne, Voltaren and Centrum; Kenvue, spun off from Johnson & Johnson with Tylenol, Motrin, Zyrtec, Benadryl, Imodium and Nicorette; Bayer, with Aleve, Claritin, Bepanthen and Rennie; Opella, Sanofi's former consumer division with Allegra, Dulcolax and Doliprane; Reckitt, with Nurofen, Mucinex, Gaviscon and Strepsils; Procter & Gamble, with Vicks, Pepto-Bismol and Metamucil; Perrigo, the largest maker of store-brand OTC medicines; Church & Dwight; Prestige Consumer Healthcare; Taisho and Rohto in Japan; and China Resources Sanjiu. Pharmacies, supermarkets, mass retailers, convenience stores and online channels sell OTC medicines.

The consumer health industry has been reshaped by corporate separations and deals. Large pharmaceutical companies spun off or sold their consumer businesses to focus on prescription medicines: Haleon listed in London in 2022, Kenvue listed in New York in 2023, and Sanofi sold a 50% controlling stake in Opella to private equity firm Clayton, Dubilier & Rice, completing the deal in April 2025. In November 2025, Kimberly-Clark agreed to acquire Kenvue for an enterprise value of about USD 48.7 billion, a deal expected to close in the second half of 2026. The pandemic caused spikes in demand for pain relievers, cold medicines and vitamins, followed by shortages of children's fever medicines in several countries during the winter of 2022. Regulators have expanded consumer access to some medicines through prescription-to-OTC switches, including the FDA's approvals of Narcan naloxone nasal spray for OTC sale in 2023 and Opill, the first daily oral contraceptive available without prescription in the United States, which launched in 2024. At the same time, regulators have reassessed some ingredients: in November 2024 the FDA proposed removing oral phenylephrine, a common decongestant, from OTC products after concluding it was ineffective, and in September 2025 US health officials suggested a link between prenatal acetaminophen use and autism, a claim disputed by medical organisations and by Kenvue, which affected Tylenol's reputation.

Market Dynamics Market Drivers • Growth of Self-Care and Consumer Health AwarenessConsumers increasingly manage minor illnesses and wellbeing themselves, supported by easy access to health information online and in pharmacies. Governments encourage self-care to reduce pressure on primary care, and pharmacists increasingly advise on and supply OTC medicines. Ageing populations use more pain relief, digestive and sleep products, while younger consumers show strong interest in wellness, vitamins and supplements.
• Prescription-to-OTC SwitchesRegulators continue to allow medicines previously requiring prescriptions to be sold over the counter, expanding the OTC market. Recent switches include naloxone for opioid overdose and daily oral contraception in the United States, as well as various allergy, digestive and pain medicines in Europe, Japan and Australia. Switches create new growth opportunities for consumer health companies and improve access for consumers.

Market Challenges • Private-Label Competition and Retail PressureStore-brand and private-label OTC medicines, supplied by manufacturers such as Perrigo, offer the same active ingredients as branded products at lower prices and hold a large share of the market in the United States and Europe. Retailers negotiate hard on prices and shelf space, and pharmacy closures in the United States reduce the number of outlets. Inflation-conscious consumers have traded down to cheaper options.
• Regulatory Scrutiny of Ingredients and ClaimsRegulators periodically review the safety and effectiveness of long-standing OTC ingredients, such as the FDA's proposal to remove oral phenylephrine. Advertising and health claims are regulated, and public controversies, such as claims about acetaminophen in pregnancy in 2025, can affect demand for established brands. Supply shortages of children's medicines and quality problems with some imported products have also drawn regulatory attention.

Market Trends • Consolidation and Portfolio Reshaping in Consumer HealthConsumer health companies are reshaping portfolios through spin-offs, acquisitions and divestments to focus on higher-growth brands and categories. The separation of Haleon, Kenvue and Opella from pharmaceutical parents created standalone companies, and Kimberly-Clark's agreed acquisition of Kenvue would combine consumer health with personal care. Private equity has become more active in consumer health, and companies are selling non-core brands to focus on leading categories.
• Digital and E-Commerce SalesOnline sales of OTC medicines have grown through Amazon, retailer websites, online pharmacies and quick-commerce delivery services, particularly in China, India and the United States. Companies use digital marketing, social media and data to reach consumers directly. Telehealth services increasingly recommend OTC products, and some pharmacies offer online consultations for minor ailments.



Segment Analysis Analgesics and cough, cold and allergy products account for the largest share of OTC drug sales, while digestive health, vitamins and skin care are major categories and newer switch categories are growing. Analgesics and pain relievers, including paracetamol or acetaminophen, ibuprofen, naproxen, aspirin and topical pain relief such as diclofenac gel, form one of the largest OTC categories, used for headaches, muscle pain, arthritis, fever and menstrual pain, with brands such as Tylenol, Panadol, Advil, Nurofen, Aleve and Voltaren. Cough, cold and flu products, including decongestants, cough suppressants, expectorants, throat lozenges and combination remedies, have seasonal demand and were affected by the FDA's review of oral phenylephrine. Allergy medicines, including antihistamines such as cetirizine, loratadine and fexofenadine and nasal steroid sprays, are widely used. Digestive health products, including antacids, acid reducers, laxatives, antidiarrhoeals and probiotics, treat heartburn, constipation and diarrhoea. Vitamins, minerals and supplements are sold as OTC medicines or food supplements depending on country rules. Dermatology products include creams for eczema, fungal infections, cold sores and acne. Smoking cessation aids, including nicotine patches, gum and lozenges, support quitting. Sleep aids, eye drops, ear care, oral care products such as medicated toothpastes, and women's health products, including emergency and daily contraception, form further categories. Naloxone for opioid overdose is a new public health category.

Tablets and capsules account for the largest share of OTC drug sales, while liquids, topical products and other formats serve specific needs and consumer preferences. Tablets and capsules are the most common form for OTC pain relievers, allergy medicines, digestive products and many other medicines, offering accurate dosing, stability and convenience. Chewable tablets, orally disintegrating tablets and gummies are popular with children and adults who dislike swallowing pills. Liquids and syrups are widely used for children's medicines and cough remedies, and shortages of children's liquid fever medicines occurred in several countries in 2022. Topical products, including creams, gels, ointments, sprays and patches, are used for pain relief, skin conditions, fungal infections and wound care, and topical analgesics have grown strongly. Nasal sprays, including decongestants, saline sprays and nasal steroids, treat congestion and allergies, and naloxone nasal spray reverses opioid overdoses. Eye and ear drops treat dryness, allergies and infections. Lozenges and throat sprays relieve sore throats. Powders and effervescent tablets are used for rehydration, pain relief and digestive health. Transdermal patches deliver nicotine for smoking cessation. Suppositories are used for fever and constipation in some markets.

Pharmacies and drugstores account for the largest share of OTC drug sales, while supermarkets and mass retailers and online channels are important and growing distribution channels. Pharmacies and drugstores are the traditional channel for OTC medicines, and in many European countries certain OTC medicines can be sold only in pharmacies, where pharmacists provide advice and ensure appropriate use. In the United States, chain pharmacies such as CVS and Walgreens have been major channels, although store closures have shifted some sales to other retailers. Supermarkets, hypermarkets and mass merchandisers, including Walmart, Target, Costco, Tesco and Carrefour, sell large volumes of OTC medicines at competitive prices, often including their own private-label ranges. Convenience stores and petrol stations sell small packs of common medicines. Online channels, including Amazon, retailer websites, online pharmacies and quick-commerce platforms, have grown rapidly, particularly for repeat purchases and in China, India and the United States. Drug and health stores in Asia, such as Watsons, Guardian, Matsumoto Kiyoshi and Welcia, combine OTC medicines with beauty and personal care. Direct-to-consumer brand websites and subscription services have emerged for vitamins and some OTC products. Healthcare professional channels, including dentists and dermatologists, recommend specific OTC products.

Branded OTC products account for the largest share of sales value, while private-label and store-brand products hold a large and growing share of volume. Branded OTC products, supported by advertising and consumer trust built over decades, account for most sales value, and leading brands such as Tylenol, Advil, Panadol, Voltaren, Zyrtec, Claritin, Nurofen, Sensodyne and Nicorette command premium prices. Consumer health companies invest in marketing, innovation in formats and flavours, and expansion into new markets and switch categories to support their brands. Private-label and store-brand products, supplied by manufacturers such as Perrigo and sold under retailer names, offer the same active ingredients at lower prices and account for a large share of volume in the United States, the UK and other markets where retailers are strong. Retailers use private labels to improve margins and attract price-conscious shoppers, and inflation in 2022 and 2023 encouraged trading down. Generic OTC products sold under manufacturer names are common in emerging markets. Traditional and herbal medicines, including traditional Chinese medicines, Ayurvedic products and Kampo medicines in Japan, form significant parts of OTC markets in Asia. The balance between branded and private-label products varies by category, with pain relief and allergy having large private-label shares and specialised products remaining more branded.

Regional Analysis North America and Europe are the largest OTC drug markets by value because of mature self-care cultures, strong consumer health brands and extensive retail networks, while Asia-Pacific is the fastest-growing region. North America, led by the United States, is one of the largest OTC markets, with high spending on pain relief, cough and cold, allergy and digestive products, strong private-label competition and extensive retail distribution through pharmacies, mass retailers and online channels. Kenvue, Haleon, Bayer, Procter & Gamble, Perrigo and Prestige are major suppliers. Regulatory developments include the switch of naloxone and daily oral contraception to OTC status, the FDA's proposed removal of oral phenylephrine and the OTC monograph reform enacted in 2020 that modernised regulation. The 2025 controversy over acetaminophen and Kimberly-Clark's agreed acquisition of Kenvue are shaping the market. Europe is a large market with strong self-care traditions and pharmacy-only sales of many medicines in countries such as Germany, France, Italy and Spain, while the UK allows wider retail sale. Haleon, Bayer, Opella and Reckitt are headquartered in Europe. Asia-Pacific is the fastest-growing region, driven by rising incomes, urbanisation and self-medication in China, India, Southeast Asia and Japan. China has a large OTC market including traditional Chinese medicines and fast-growing online sales, Japan has a mature market with strong domestic companies and drugstore chains, and India's OTC market is expanding through pharmacies and e-commerce. Latin America, led by Brazil and Mexico, has large OTC markets where many medicines are bought without prescriptions, and the Middle East and Africa are growing with expanding pharmacy chains.

Key Developments November 2025: Kimberly-Clark agreed to buy Kenvue, owner of Tylenol, Listerine and Zyrtec, for an enterprise value of about USD 48.7 billion, with completion expected in the second half of 2026.
September 2025: US health officials announced they would seek label changes suggesting a link between acetaminophen use in pregnancy and autism, a claim disputed by medical groups and Kenvue.
April 2025: Sanofi completed the sale of a 50% controlling stake in its consumer health business Opella to Clayton, Dubilier & Rice, creating a standalone consumer health company.
November 2024: The FDA proposed removing oral phenylephrine from its list of approved OTC ingredients after concluding it is not effective as a nasal decongestant.
March 2024: Perrigo began selling Opill, a progestin-only daily oral contraceptive, without a prescription in the United States after its FDA approval in 2023.
March 2023: The FDA approved naloxone nasal spray for over-the-counter sale, making the opioid overdose reversal medicine available without a prescription.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global OTC Drugs Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Product Category
• Analgesics
• Cough, Cold and Allergy Products
• Digestive Health Products
• Vitamins, Minerals and Supplements
• Dermatology Products
• Smoking Cessation Aids
• Other OTC Products

By Dosage Form
• Tablets and Capsules
• Liquids and Syrups
• Topical Products
• Nasal and Eye Products
• Other Forms

By Distribution Channel
• Pharmacies and Drugstores
• Supermarkets and Mass Retailers
• Online Channels
• Convenience Stores

By Brand Type
• Branded Products
• Private-Label Products
• Traditional and Herbal Medicines